Clinical bottom line
Novel therapies targeting key inflammatory pathways have expanded treatment options for enthesitis in psoriatic arthritis (PsA), a major contributor to morbidity. Biologic agents including IL-17 and IL-23 inhibitors, as well as T-cell co-stimulation modulators like abatacept, demonstrate efficacy in reducing enthesitis severity. Adjunctive strategies such as weight loss may further improve outcomes. However, heterogeneity in assessment methods and patient response necessitate individualized treatment plans and further research to optimize management.
What the evidence shows
Enthesitis, inflammation at tendon and ligament insertion sites, is a hallmark of PsA and correlates with disease activity and functional impairment. Mease et al. (2011) provide validated measures for enthesitis assessment, including the Leeds Enthesitis Index (LEI) and Spondyloarthritis Research Consortium of Canada (SPARCC) index, facilitating standardized evaluation in clinical trials and practice.
Arraf et al. (2025) review novel pharmacotherapies in PsA, highlighting IL-17 inhibitors (secukinumab, ixekizumab) and IL-23 inhibitors (guselkumab) as effective in reducing enthesitis. These agents target cytokines central to PsA pathogenesis, with clinical trials demonstrating significant improvements in enthesitis scores and patient-reported outcomes.
Noisette et al. (2018) discuss abatacept, a selective T-cell co-stimulation modulator, which has shown efficacy in PsA patients with enthesitis, particularly those with inadequate response to TNF inhibitors. Patient selection based on immunophenotyping may optimize abatacept use.
Williams et al. (2024) emphasize the role of metabolic syndrome and obesity in PsA severity, noting that weight loss acts as a disease-modifying intervention that can reduce enthesitis and overall inflammation, complementing pharmacologic therapies.
Ultrasound imaging enhances detection and monitoring of enthesitis, as reported in a 2019 case medical research study, enabling objective assessment of treatment response.
Shenoi et al. (2024) provide insights from juvenile idiopathic arthritis treatment paradigms, underscoring the importance of early intervention and targeted therapies to prevent enthesitis-related damage.
D’Aprile et al. (2014) describe MRI features of enthesitis in PsA, supporting imaging as an adjunct to clinical evaluation.
Caveats and uncertainty
Variability in enthesitis scoring systems and lack of consensus on optimal assessment tools limit comparability across studies.
Long-term comparative effectiveness data for newer biologics in enthesitis are sparse.
Response heterogeneity necessitates biomarkers or clinical predictors to guide therapy selection.
Weight loss interventions require integration into multidisciplinary care but may face adherence challenges.
Imaging modalities, while informative, may not be universally accessible.
How this may change practice
Clinicians should incorporate validated enthesitis indices and imaging to accurately assess and monitor enthesitis in PsA.
IL-17 and IL-23 inhibitors represent effective options for patients with refractory enthesitis, with abatacept as a potential alternative in selected cases.
Addressing metabolic comorbidities through weight management may enhance therapeutic response.
Personalized treatment strategies combining pharmacologic and lifestyle interventions may optimize outcomes.
Ongoing research into biomarkers and standardized assessment tools will refine enthesitis management.